NFIL3 is a negative regulator of hepatic gluconeogenesis

Geon Kang, Hye Sook Han, Seung-Hoi Koo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective Nuclear factor interleukin-3 regulated (NFIL3) has been known as an important transcriptional regulator of the development and the differentiation of immune cells. Although expression of NFIL3 is regulated by nutritional cues in the liver, the role of NFIL3 in the glucose metabolism has not been extensively studied. Thus, we wanted to explore the potential role of NFIL3 in the control of hepatic glucose metabolism. Materials/Methods Mouse primary hepatocytes were cultured to perform western blot analysis, Q-PCR and chromatin immunoprecipitation assay. 293 T cells were cultured to perform luciferase assay. Male C57BL/6 mice (fed a normal chow diet or high fat diet for 27 weeks) as well as ob/ob mice were used for experiments with adenoviral delivery. Results We observed that NFIL3 reduced glucose production in hepatocytes by reducing expression of gluconeogenic gene transcription. The repression by NFIL3 required its basic leucine zipper DNA binding domain, and it competed with CREB onto the binding of cAMP response element in the gluconeogenic promoters. The protein levels of hepatic NFIL3 were decreased in the mouse models of genetic- and diet-induced obesity and insulin resistance, and ectopic expression of NFIL3 in the livers of insulin resistant mice ameliorated hyperglycemia and glucose intolerance, with concomitant reduction in expression of hepatic gluconeogenic genes. Finally, we witnessed that knockdown of NFIL3 in the livers of normal chow-fed mice promoted elevations in the glucose levels and expression of hepatic gluconeogenic genes. Conclusions In this study, we showed that NFIL3 functions as an important regulator of glucose homeostasis in the liver by limiting CREB-mediated hepatic gluconeogenesis. Thus, enhancement of hepatic NFIL3 activity in insulin resistant state could be potentially beneficial in relieving glycemic symptoms in the metabolic diseases.

Original languageEnglish
Pages (from-to)13-22
Number of pages10
JournalMetabolism: Clinical and Experimental
Volume77
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Gluconeogenesis
Interleukin-3
Liver
Glucose
Hepatocytes
Insulin
Diet
Leucine Zippers
Glucose Intolerance
Chromatin Immunoprecipitation
Genetic Models
Metabolic Diseases
Response Elements
High Fat Diet
Luciferases
Inbred C57BL Mouse
Hyperglycemia
Genes
Cues
Insulin Resistance

Keywords

  • Gluconeogenesis
  • Liver
  • NFIL3
  • Transcriptional repressor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

NFIL3 is a negative regulator of hepatic gluconeogenesis. / Kang, Geon; Han, Hye Sook; Koo, Seung-Hoi.

In: Metabolism: Clinical and Experimental, Vol. 77, 01.12.2017, p. 13-22.

Research output: Contribution to journalArticle

@article{fea8f99c0e7849edb3edd8caf8e3e541,
title = "NFIL3 is a negative regulator of hepatic gluconeogenesis",
abstract = "Objective Nuclear factor interleukin-3 regulated (NFIL3) has been known as an important transcriptional regulator of the development and the differentiation of immune cells. Although expression of NFIL3 is regulated by nutritional cues in the liver, the role of NFIL3 in the glucose metabolism has not been extensively studied. Thus, we wanted to explore the potential role of NFIL3 in the control of hepatic glucose metabolism. Materials/Methods Mouse primary hepatocytes were cultured to perform western blot analysis, Q-PCR and chromatin immunoprecipitation assay. 293 T cells were cultured to perform luciferase assay. Male C57BL/6 mice (fed a normal chow diet or high fat diet for 27 weeks) as well as ob/ob mice were used for experiments with adenoviral delivery. Results We observed that NFIL3 reduced glucose production in hepatocytes by reducing expression of gluconeogenic gene transcription. The repression by NFIL3 required its basic leucine zipper DNA binding domain, and it competed with CREB onto the binding of cAMP response element in the gluconeogenic promoters. The protein levels of hepatic NFIL3 were decreased in the mouse models of genetic- and diet-induced obesity and insulin resistance, and ectopic expression of NFIL3 in the livers of insulin resistant mice ameliorated hyperglycemia and glucose intolerance, with concomitant reduction in expression of hepatic gluconeogenic genes. Finally, we witnessed that knockdown of NFIL3 in the livers of normal chow-fed mice promoted elevations in the glucose levels and expression of hepatic gluconeogenic genes. Conclusions In this study, we showed that NFIL3 functions as an important regulator of glucose homeostasis in the liver by limiting CREB-mediated hepatic gluconeogenesis. Thus, enhancement of hepatic NFIL3 activity in insulin resistant state could be potentially beneficial in relieving glycemic symptoms in the metabolic diseases.",
keywords = "Gluconeogenesis, Liver, NFIL3, Transcriptional repressor",
author = "Geon Kang and Han, {Hye Sook} and Seung-Hoi Koo",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.metabol.2017.08.007",
language = "English",
volume = "77",
pages = "13--22",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - NFIL3 is a negative regulator of hepatic gluconeogenesis

AU - Kang, Geon

AU - Han, Hye Sook

AU - Koo, Seung-Hoi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Objective Nuclear factor interleukin-3 regulated (NFIL3) has been known as an important transcriptional regulator of the development and the differentiation of immune cells. Although expression of NFIL3 is regulated by nutritional cues in the liver, the role of NFIL3 in the glucose metabolism has not been extensively studied. Thus, we wanted to explore the potential role of NFIL3 in the control of hepatic glucose metabolism. Materials/Methods Mouse primary hepatocytes were cultured to perform western blot analysis, Q-PCR and chromatin immunoprecipitation assay. 293 T cells were cultured to perform luciferase assay. Male C57BL/6 mice (fed a normal chow diet or high fat diet for 27 weeks) as well as ob/ob mice were used for experiments with adenoviral delivery. Results We observed that NFIL3 reduced glucose production in hepatocytes by reducing expression of gluconeogenic gene transcription. The repression by NFIL3 required its basic leucine zipper DNA binding domain, and it competed with CREB onto the binding of cAMP response element in the gluconeogenic promoters. The protein levels of hepatic NFIL3 were decreased in the mouse models of genetic- and diet-induced obesity and insulin resistance, and ectopic expression of NFIL3 in the livers of insulin resistant mice ameliorated hyperglycemia and glucose intolerance, with concomitant reduction in expression of hepatic gluconeogenic genes. Finally, we witnessed that knockdown of NFIL3 in the livers of normal chow-fed mice promoted elevations in the glucose levels and expression of hepatic gluconeogenic genes. Conclusions In this study, we showed that NFIL3 functions as an important regulator of glucose homeostasis in the liver by limiting CREB-mediated hepatic gluconeogenesis. Thus, enhancement of hepatic NFIL3 activity in insulin resistant state could be potentially beneficial in relieving glycemic symptoms in the metabolic diseases.

AB - Objective Nuclear factor interleukin-3 regulated (NFIL3) has been known as an important transcriptional regulator of the development and the differentiation of immune cells. Although expression of NFIL3 is regulated by nutritional cues in the liver, the role of NFIL3 in the glucose metabolism has not been extensively studied. Thus, we wanted to explore the potential role of NFIL3 in the control of hepatic glucose metabolism. Materials/Methods Mouse primary hepatocytes were cultured to perform western blot analysis, Q-PCR and chromatin immunoprecipitation assay. 293 T cells were cultured to perform luciferase assay. Male C57BL/6 mice (fed a normal chow diet or high fat diet for 27 weeks) as well as ob/ob mice were used for experiments with adenoviral delivery. Results We observed that NFIL3 reduced glucose production in hepatocytes by reducing expression of gluconeogenic gene transcription. The repression by NFIL3 required its basic leucine zipper DNA binding domain, and it competed with CREB onto the binding of cAMP response element in the gluconeogenic promoters. The protein levels of hepatic NFIL3 were decreased in the mouse models of genetic- and diet-induced obesity and insulin resistance, and ectopic expression of NFIL3 in the livers of insulin resistant mice ameliorated hyperglycemia and glucose intolerance, with concomitant reduction in expression of hepatic gluconeogenic genes. Finally, we witnessed that knockdown of NFIL3 in the livers of normal chow-fed mice promoted elevations in the glucose levels and expression of hepatic gluconeogenic genes. Conclusions In this study, we showed that NFIL3 functions as an important regulator of glucose homeostasis in the liver by limiting CREB-mediated hepatic gluconeogenesis. Thus, enhancement of hepatic NFIL3 activity in insulin resistant state could be potentially beneficial in relieving glycemic symptoms in the metabolic diseases.

KW - Gluconeogenesis

KW - Liver

KW - NFIL3

KW - Transcriptional repressor

UR - http://www.scopus.com/inward/record.url?scp=85030709456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030709456&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2017.08.007

DO - 10.1016/j.metabol.2017.08.007

M3 - Article

VL - 77

SP - 13

EP - 22

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

ER -